ライフサイエンスコーパス: fertility preservation

1 to allow for the widest array of options for fertility preservation.

2 making about future conception attempts and fertility preservation.

3 ell research and potential future utility in fertility preservation.

4 ilure are addressed, followed by options for fertility preservation after stem cell transplantation.

5 d treatment regimens and allows risk-adapted fertility preservation and comprehensive support during

6 Notable needs also include fertility preservation and navigation through the multip

7 with cancer, quality-of-life issues, such as fertility preservation and parenthood, have become an es

8 sociated gonadotoxicity, current methods for fertility preservation, and new scientific advances in t

9 s opportunities in male reproductive health, fertility preservation, and regenerative medicine.

10 eatment, the evolving information related to fertility preservation, and the ethical issues involved,

11 To preserve the full range of options, fertility preservation approaches should be considered a

12 east cancer were prospectively evaluated for fertility preservation before adjuvant chemotherapy.

13 Nevertheless, consideration of fertility preservation before cancer treatment remains i

14 immediate revascularization, ensuring better fertility preservation, but the best cryopreservation me

15 of sterility, and some patients are offered fertility preservation by cryopreservation of the ovaria

16 trozole and gonadotropins for the purpose of fertility preservation by embryo or oocyte cryopreservat

17 patients with cancer should be referred for fertility preservation counselling quickly to help with

18 readily accessible pharmacologic approach to fertility preservation during conventional chemotherapy.

19 The field of oncofertility, or fertility preservation for patients facing a cancer diag

20 of fertility-related information and use of fertility preservation (FP) in connection with cancer tr

21 ch to ovarian stimulation for the purpose of fertility preservation (FP) in women with breast cancer

22 ussing treatment-related fertility risks and fertility preservation (FP) options with patients and in

23 atient recall of discussion and referral for fertility preservation (FP) show that less than half rec

24 All approaches to fertility preservation have specific challenges in child

25 it should not be recommended as standard for fertility preservation in patients with lymphoma.

26 is review focuses on the current options for fertility preservation in young women facing the risk of

27 Options for fertility preservation include cryopreservation of embry

28 ence with these techniques in the setting of fertility preservation is in its infancy.

29 Fertility preservation is often possible in people under

30 nadotropins and letrozole for the purpose of fertility preservation is unlikely to cause substantiall

31 icancer therapy is a promising technique for fertility preservation mainly in children and young wome

32 Fertility preservation methods are used infrequently in

33 have culminated in an increased interest in fertility preservation methods in girls and young women

34 e trials examining the success and impact of fertility preservation methods in people with cancer.

35 Other fertility preservation methods should be considered inve

36 ce and are widely available; other available fertility preservation methods should be considered inve

37 ians of children) and be prepared to discuss fertility preservation options and/or to refer all poten

38 ve years and be prepared to discuss possible fertility preservation options or refer appropriate and

39 Appropriate fertility-preservation options should be offered.

40 communication, and developmental factors to fertility preservation outcomes.

41 patients at risk and initiate management for fertility preservation prior to beginning therapy.

42 reezing and vitrification of whole ovary for fertility preservation purposes, in an ewe model.

43 Options for fertility preservation remain limited but are improving

44 pretreatment patient counselling and use of fertility preservation services.

45 al support, nutritional, rehabilitative, and fertility preservation services; programme value, includ

46 In these cases, fertility preservation should be discussed and initiated

47 ility concerns affect treatment decisions or fertility preservation strategies at the time of initial

48 minority of women currently pursue available fertility preservation strategies in this setting.

49 ental pretreatment as well as post-treatment fertility preservation strategies, including barriers an

50 docrine therapy for < 5 years; 65 (10%) used fertility preservation strategies.

51 To ensure safety of this fertility preservation strategy, methods are needed to i

52 uture biologic child, there are a variety of fertility preservation techniques that should be conside

53 Some fertility preservation techniques, such as semen and emb

54 ncer should be counseled about the available fertility preservation techniques.

55 A number of fertility-preservation techniques have been developed an

56 ure studies aiming at improved chelation for fertility preservation, whereas NTBI and labile plasma i